



Research News

**Message From the Vice President for Health Sciences Research, LUHS/Senior Associate Dean of Research, SSOM
Richard H. Kennedy, PhD**



Changes in the Office of Research Services for the Health Sciences

I am certain that everyone on campus is aware of the positive impact that Dr. Linda Brubaker, Assistant Dean of Clinical and Translational Research in the Stritch School of Medicine (SSOM), has had on research operations, especially the clinical research enterprise. During the past several months, there have been several additional changes that I believe will strengthen our research programs in both SSOM and the Niehoff School of Nursing (NSON):

Appointment of Assistant Dean for Basic Science Research and Postdoctoral Affairs

As many of you know, Dr. Ruben Mestril, Professor of Physiology, has been appointed by Dean Lee to serve half-time as the Assistant Dean of Basic Science Research and Postdoctoral Affairs in SSOM. Ruben's initial duties in this role are to serve as administrative liaison for the Institutional Biosafety Committee (IBC) and to develop an organized program for postdoctoral trainees on campus. Since Dr. Mestril served previously as Chair of the IBC, Dr. Leanne Cribbs has agreed to assume that role. I am sure Ruben and Leanne will work together with members of the IBC to insure that individual investigators and the institution are meeting federal regulations regarding bio-hazards while keeping administrative burden on faculty to a minimum. With respect to the Postdoctoral Program, Dr. Mestril has developed an initial draft of an organizational structure and the elements to be included in a program that would support the career objectives of our postdoctoral trainees. He has been monitoring the National Postdoctoral Association and has used many of their concepts in his preliminary draft. Once Ruben believes he has completed implementation of strong IBC and postdoctoral initiatives, he will assume leadership roles in both Animal Care/IACUC and Research Integrity.

Changes in Technology Transfer/Intellectual Property (TT/IP)

Donna Bobrowicz, JD, the half-time Technology Transfer Specialist in ORS, left us in April to assume a full-time position in industry. I would like to thank Donna for organizing our intellectual property/patent files and beginning to educate us on many of the issues associated with inventions and their protection. In Donna's absence we have assessed our program and decided to use a slightly different approach for TT/IP on campus. In the new structure Mary Donnelly, JD, Office of Research Services Staff Attorney, will serve as point of contact for faculty. Invention Disclosures, using the form available on our website, should be submitted to Mary, and questions you may have regarding inventions and technology transfer should be directed to her. However, rather than trying to maintain all the operations associated with TT/IP "in house", we have decided to sign an agreement with outside consultants who will be engaged for issues related to technology assessment, marketing, technology protection, and licensing. Mary will forward disclosures and inquiries to these consultants as they arise. I believe this structure will provide a more comprehensive and effective system for our investigators.

Director of Research Compliance and Safety

As indicated in Dr. Brubaker's comments below, Elaine Fluder, MSN has resigned as Director of Research Compliance and Safety to assume the role of Director of Human Research Protections. The Director of Research Compliance and Safety reports directly to Maria Pekar, MBA, JD, Associate Vice President for Corporate Compliance and Internal Audit, not the Vice President for Health Sciences Research; however, this individual obviously plays a significant role in compliance issues related to research operations at SSOM and NSON. During her time as Director of Research Compliance and Safety, Elaine did a great job of identifying our research compliance issues and organizing her office and associated committee structure into an operation that addresses all regulatory issues while facilitating faculty effort as much as possible. I am sure that she will take the same organizational skills, commitment and understanding of human research to her new

role; there is no doubt that faculty involved in clinical research will find Elaine's new role to be beneficial. Meanwhile, Maria Pekar will initiate a search for a new Director of Research Compliance and Safety. During this search process, Judith Blacklidge, the recently hired Compliance Auditor in the Corporate Compliance Office, has agreed to serve as Interim Director of Research Compliance and Safety. Ms. Blacklidge's extensive experience in human research provides the background required to serve in this interim role. I am certain that operations related to research compliance will not be affected during this transition period.

In This Issue

Message from Dr. Kennedy	1
Message from Dr. Brubaker	2
Message from Dr. Mestril	3
Message from the ORS office	4
Faculty/Graduate student Highlights	6
Department and Institute Highlights	8
Research Activity at LUMC	9

**Message From the Assistant Dean of Clinical and Translational Research
Linda Brubaker, MD, MS.**



Human Research and the IRB

For years, Kenneth Micetich, MD has balanced his clinical role as a hematologist-oncologist with his role as the Institutional Review Board Chair. Despite his busy clinical duties, he has overseen the monthly meetings of the IRB, maintained IRB membership and complied with the federal regulations governing the conduct of human research at Loyola. **Although clinical investigators are aware that they could not conduct their scientific research without the work of the IRB**, many investigators are not fully aware of the impact of the federal regulations on our system. This short piece will introduce you to new members of the IRB team, reacquaint you with the workings of the IRB, describe our plans for streamlining IRB processes and invite your constructive suggestions for improved protection of our human research volunteers.

- New members of the administrative IRB team. Ms. Peggy Johnson provides day-to-day support in her role as the IRB secretary. She maintains organized files for all human research projects, facilitates dissemination of materials for IRB committee members, and can answer many questions regarding the IRB process. New to the team is Elaine Fluder, RN, MSN, the Director of Human Subjects Protection. In this role, Ms. Fluder will provide day-to-day continuity for research team members in their interface with the IRB, including providing timely communications regarding the status of reviews following IRB meetings. In addition, she is a skilled research member who can provide pre-review of documents prior to formal IRB submission. We hope that investigators will take advantage of this pre-review process to facilitate timely approval of their proposals. Dr. Micetich continues to serve as IRB Chair and remains responsible for the conduct of specific research reviews. The IRB administrative team is under my direction and in that role, I am responsible for organizing appropriate systems and support for the function of the IRB Committee. Our whole team is available to answer questions and provide support to facilitate the appropriate conduct and review of human subject research.
- It may be worthwhile to reacquaint yourself with the workings of the Loyola IRB. The IRB meets monthly at pre-set dates which are available on the ORS website. Materials for review at those meetings must be received approximately two weeks prior to the meeting date to allow dissemination and adequate time for the volunteer committee members to review the materials. Dr. Micetich (IRB Chair) or his designee conducts the meeting in accordance with federal regulations. Immediately following the meeting, the disposition of your submission is sent to you. Individuals who are unfamiliar with this process are encouraged to contact a member of the IRB administrative team with questions or to clarify their expectations. For certain research submissions, an “expedited” review may occur without a meeting of the full committee. It is the prerogative of the IRB Chair to provide such a review in concordance with the federal regulations which govern expedited review. For most projects, you should plan an IRB submission at least two months prior to your desired research start date. As a general rule, more complex and/or more invasive projects may require at least one resubmission following initial IRB review of the project. It is helpful to plan accordingly.
- Our strategic plan includes expansion of our clinical research. In order to accomplish this, we want to take every opportunity to streamline the IRB process. We have taken steps to initialize this process by allowing concurrent processes instead of sequential processes whenever possible. Examples of this include our new clinical marketing language site, which allow simultaneous review of marketing language and IRB review of the proposal itself. Although no marketing language can be used prior to IRB approval, we hope that the significantly shortened time to marketing approval will help research teams disseminate knowledge of their studies and enhance recruitment. In addition, by the time you are reading this newsletter, we plan to have a kiosk in the Ambulatory Center that will allow patients, families and friends to review the available clinical research by doctor and subject area. This is also available on the main LUHS page.
- As a clinical researcher yourself, you are likely to have constructive suggestions on ways we can improve you ability to interact with the IRB. Please send those suggestions to me at LBrubaker@lumc.edu. I never turn away a brilliant idea!

Loyola clinical researchers have huge potential for enhancing clinical research within our system. It helps everyone when knowledge of processes and expectations of the IRB interactions are aligned. These elements will form a central core of our Association for the Accreditation of Human Research Protection Program (AAHRPP) accreditation which is scheduled for 2009. AAHRP accreditation is essentially the “stamp of approval” for an institution that conducts human research and will require review and updating of research-related policies. The next newsletter will contain information about this process and the Loyola timeline.

**Message From the Assistant Dean for Basic Research and Postdoctoral Affairs
Ruben Mestrl, PhD.**



It is an honor to assume the duties of Assistant Dean for Basic Research and Postdoctoral Affairs. I have previously been chairing the Institutional Biohazard Committee, a duty I will pass on to Dr. Leanne Cribbs this coming August. In these past two years, the IBC has successfully developed several mechanisms to streamline the process of protocol application, submission and approval. Presently, the whole process should not take more than 4 weeks. Efforts have been made to establish a direct interaction with the IACUC to permit the rapid review and approval of protocols involving the use of biohazardous materials in animals. It is important to make investigators aware that all IBC protocols are now on a 3 year review cycle. Any IBC protocol older than 3 years will need to be renewed if the investigator plans to continue working with biohazardous materials. In my new role I shall be sitting on both committees and serve as an additional route of communications between both bodies.

In my new position, I will also be attending to the needs of the postdoctoral trainees on our campus. Recent high profile cases of scientific misconduct have resulted in a strong interest by Federal funding agencies to require that all science trainees receive proper training concerning responsible conduct of research. So among the topics that will be of interest to all postdoctoral fellows such as grant writing, job perspectives, we also plan to include topics related to responsible conduct of research. The Office for Research Integrity strongly recommends that postdoctoral fellows should be trained in subjects such as mentor/trainee responsibilities, peer review, collaborative science, research misconduct, data acquisition, management, sharing and ownership, publication practices and responsible authorship, etc. Therefore, starting September 2008, a monthly brown-bag lunch will provide a forum for all affairs affecting postdoctoral fellows. The order of topics to be covered, meeting day and time will be established after reviewing the survey that is currently circulating among postdoctoral fellows. Our ultimate goal is to establish a chapter of the National Postdoctoral Association on our campus. I am counting on our Faculty especially on those who serve as postdoctoral advisors to support this effort to provide our postdoctoral fellows with a forum to facilitate their professional growth.



Jamie Caldwell,
Director of the Office of Research Services (ORS)

With the latest rounds of electronic submissions, I wanted to take this opportunity to thank the entire Faculty who submitted proposals for review and approval and the Grant Administrators and Staff who assisted in the process. During the April, May, June and deadlines, the Office of Research Services for the Health Sciences (ORSHS) processed 77 grant proposals for a total requested cost of \$61,377,544. *(These are preliminary numbers)*

New Faculty Hires

As we welcome new Faculty to Loyola, I would like to remind departments to notify the Office of Research Services for the Health Sciences during the **recruitment process** if faculty will be transferring grants with them to Loyola. There is a "Change in Grantee Institution" process which can take a few weeks to finalize. Advance notice would greatly minimize the delay of researchers getting their projects running.

NIH Updates Spring/Summer 2008

New Tools for NIH Funding Data

Research Portfolio Online Reporting Tool (RePORT)

Replacement for traditional Award Information and Data Webpage

New site offers:

Quick access to standard reports and data.

Search tools for locating data and reports quickly and easily.

FAQs on how success rates are computed and questions on the NIH budget.

Links to funding estimates for certain research areas, conditions, and diseases

President's Budget Request for FY 2009

Requested a total of \$29.457 billion for NIH

Same as FY2008

Estimated 9,757 new and competing renewal Research Project Grants

Approximately 14 less than FY2008 and 566 less than FY2007

President's Budget Request FY 2009 Areas of Focus

Bolster funding to new investigators especially in novel and recently emerging areas of opportunity – continue to sustain 1,500 new investigators each year

Encourage established investigators through investigator-initiated research projects, which remain the workhorse of NIH research.

Roadmap/Common Fund – Incubator for new ideas and initiatives that accelerate the pace of discovery

Global Fund for HIV/AIDS, Tuberculosis and Malaria

NRSA Funding Policy – Proposed 1% stipend increase

CSR Shortens Review for New Investigators

New investigators unsuccessful in a R01 grant submission who are **readily able** to address the concerns and issues identified in the Summary Statement may shorten time to next review.

Available for all CSR study sections reviewing new investigator R01 applications submitted for standard receipt dates. (Does not include RFAs and PARs with special receipt dates).

Policies and practices include:

Resubmission applications to be considered at the next cycle must be submitted by March 20, July 20, or Nov 20.

New Investigators who do not choose this option may use the standard resubmission dates for subsequent submissions (March 5, July 5, or November 5)



Research News

Revised Policy on Concurrent Support for Career Awards

Recipients of mentored career development (K) awards may reduce effort on their K award in its final two years when they successfully compete for a peer-reviewed research grant from any Federal agency.

Effort may be reduced to no less than 6 person-months (or 50% full-time professional effort) and replaced with effort from the research award so the total research effort commitment remains at 9 person-months (75% effort).

K awardee must be one of the named PIs on a competing research grant application or sub-project director on multi-component research or center grant or coop agreement.

FY 2008 Legislative Mandates

Most provisions identical to FY 2005-2007

- Ban on False and Deliberately Misleading Scientific Information
Similar to existing research integrity, fraud and false claims restrictions; no significant changes for grantees
- Restriction on Employment of Unauthorized Alien Workers
Similar to existing Immigration and Nationality Act; no significant changes for grantees
- NIH Public Access Policy (No longer optional – compliance mandated by law)
Applicable to:
 - Peer-reviewed articles,
 - Accepted for publication on or after 4/7/08, and
 - Arising from direct grant or contract funds active in FY 2008, and beyond.Full-text articles to be publicly available on NLM's PubMed Central no later than 12 months after date of publication

Unallowable Costs for Activities Involving Animals

Institutions are not permitted to charge grants or contracts for animal activities when terms and conditions are not upheld.

- Absence/suspension of valid Assurance
- Absence/suspension of valid IACUC approval:
 - Failure to obtain IACUC approval
 - IACUC approval has expired
 - Suspension of IACUC approval

Employee Highlights



Bruce Cuevas, PhD., Assistant Professor of Pharmacology and Experimental Therapeutics

Dr. Cuevas' graduate research and training took place at the University of Texas at Houston, MD Anderson Cancer Center, where he studied under the supervision of Dr. Gordon B. Mills and focused on signal transduction pathways involved in tumorigenesis. After completing graduate studies, he accepted a postdoctoral position at the University of Colorado in the laboratory of Dr. Gary L. Johnson, with whom he began a long and productive association. When Dr. Johnson accepted the chairmanship of the Pharmacology department at the University of North Carolina, Dr. Cuevas moved with him and took up a faculty position in the department. This past winter, he accepted a position in the Department of Pharmacology and Experimental Therapeutics here at Loyola, and started his lab here last March. Throughout his career, he has had an abiding interest in cancer metastasis.

The majority of cancer deaths are due to the formation of secondary tumors called metastases. Metastatic tumors are formed by tumor cells that move from the primary tumor mass, past matrix barriers into the organ parenchyma. Therefore, two key requirements for metastasis of solid tumors are tissue remodeling and tumor cell migration, and both of these crucial cellular functions are regulated by cell signaling networks. Importantly, metastases are frequently less responsive to current therapeutic strategies, thus a greater understanding of metastasis-related mechanisms and genetics is necessary to develop new effective anti-metastasis therapies. Research in Dr. Cuevas' lab is directed toward defining the signaling networks required for tumor metastasis. He has shown that the MAP3Kinase MEKK1 regulates cell migration and protease expression, and has observed that loss of MEKK1 delays breast tumor metastasis in a transgenic mouse model. This influence is exerted, in part, through control of tumor cell gene expression, and he has demonstrated that MEKK1 activity regulates gene expression by controlling AP-1 transcription factor expression and activity. AP-1 controls expression of multiple genes that regulate cell proliferation and survival, as well as genes required for tissue remodeling. Thus one focus of his lab is the identification of MEKK1-dependent genes that control metastasis-related tumor cell function. In his new lab here at Loyola, he will expand his inquest to include multiple members of the MAP3Kinase family, since they are important regulators of multiple metastasis-related tumor cell functions. Dr. Cuevas' long-term goal is to define the signaling processes required for tumor progression. Metastasis regulators discovered in his studies will be used to develop new models of tumor progression, with a goal of identifying potential targets for therapeutic intervention in the treatment of tumor metastasis.



Mitchell Denning, PhD., Associate Professor of Pathology

Dr. Denning received his B.S. in Biochemistry from the University of Arizona and his Ph.D. from the University of Wisconsin-Madison in Human Cancer Biology, followed by a postdoctoral fellowship at the National Cancer Institute at NIH. His work at the NIH was on mouse skin carcinogenesis, where he focused on the differences in the regulation and function of protein kinase C (PKC) isoforms in the context of keratinocyte malignant transformation. He found that different PKC isoforms expressed in mouse keratinocytes had unique functions, and that the earliest genetic change in mouse skin chemical carcinogenesis, namely an activating mutation in H-Ras, selectively modulated the activity of different PKC isoforms. The mouse skin carcinogenesis model was especially suited for studying PKC function since one of the chemicals used to elicit tumors, the phorbol ester TPA, is a direct agonist of many PKC isoforms. However, the etiology of chemically-induced mouse skin tumors is very different from UV-induced human skin cancers; thus the significance of these findings to human cancer was unclear.

In 1997 he joined the Skin Cancer Research Program here in the Cancer Center at Loyola since he wanted to extend his PKC studies into human skin cancer because of its unique UV radiation etiology. One of his first experiments here hit pay dirt, and he demonstrated that the causative agent for human skin cancers, UV radiation, selectively activated the delta isoform of PKC via a novel mechanism. Furthermore, the activation of PKC-delta led to apoptosis, an important tumor suppressor mechanism for many types of cancer. These observations led to a JBC publication in his first year, and subsequent support by an NIH R01 grant on his first submission (times were very different then).

Dr. Denning's lab continues to follow up on the tumor suppressive functions of PKC-delta, with the goal of developing therapeutic agents that can activate or induce PKC-delta to treat cutaneous squamous cell carcinoma. They have also expanded to investigate the roles of other PKC isoforms (i.e. PKC-alpha) in human squamous cell carcinoma, and the role of PKC signaling in malignant melanoma, the most deadly type of human skin cancer. Their studies are currently funded by the NIH and American Cancer Society, and are very collaborative. His interactions with all current and past members of the Skin Cancer Research Program, especially Drs. Leonid Sitailo, Jian-Zhong Qin, and Brian Nickoloff, are greatly appreciated.

Graduate Student Highlights



John Karavitis, B.S., Graduate Student, Department of Cell Biology, Neurobiology & Anatomy and the Burn and Shock Trauma Institute

John Karavitis grew up in Skokie, a city just north of Chicago Illinois. He graduated from the University of Illinois at Chicago with a Bachelors degree in Biology in 2000. From there, he continued his studies and began doing research on interchromosomal linking elements and how cell matrix can play a role in gene expression under the guidance of Dr. Andrew Maniotis in the department of Pathology. John then moved to the east coast to continue his research and graduate training at Children's Hospital at Harvard Medical School. There he spent two years under the Dr. Donald Ingber in the department of Vascular Biology. He was involved a number of projects, including trying to elucidate the effects that mechanical stress has on cellular signaling.

In 2004, Mr. Karavitis came to Loyola and matriculated into the PhD Program in the Department of Cell Biology, Neurobiology, and Anatomy. He found the interdisciplinary curriculum to be most advantageous for allowing broader range of research opportunities. After completing two research rotations, John joined the laboratory of Dr. Elizabeth Kovacs in June, 2005. Dr. Kovacs' research program focuses on the effects of alcohol and advanced aging on inflammatory responses after injury. He became interested in the recent observation that acute alcohol exposure was immunosuppressive, resulting in, for example, in the inability of subsets of white blood cells to communicate with one another through the production of pro-inflammatory cytokines. John's project focuses on elucidating the mechanism by which alcohol inhibits macrophage phagocytosis. Through his work over the past two years, he has characterized a novel pathway of how alcohol may be inhibiting normal macrophage function. These studies reveal that the activation of the small GTPase Rho is decreased by exposure to binge levels of alcohol. In addition to the importance of small GTPases in phagocytosis, improper small GTPase regulation may result in a dysregulation of a number of functions including cell proliferation, migration, and cytokine production.

Overall, Mr. Karavitis has found his graduate training to be a great experience, both personally and professionally. He is glad that he chose Loyola University Chicago and the Department of Cell Biology, Neurobiology and Anatomy. Dr. Kovacs has been instrumental in guiding John not only in his research, but also in showing him the importance of being an active participant at scientific meetings, presenting data, and pursuing scientific awards and funding. John's graduate study is currently supported by the National Research Service Award (NRSA) that he received from the National Institute of Alcohol Abuse and Alcoholism (NIAAA) of the NIH. Prior to this he was supported by Dr Kovacs' Institutional Training Grant awarded by the NIAAA. He has a first-authored manuscript which is in press in the Journal of Interferon and Cytokine Research as well as two review articles that he has co-authored. John has presented six posters at various scientific meetings, including at the Annual Conference of the Shock Society, Research Society on Alcoholism, Annual Meeting of the Society for Leukocyte Biology, and Alcohol and Immunology Research Interest Group Meeting and has received travel awards for three of these meetings. Among his oral presentations, John gave a talk entitled "Acute ethanol exposure impairs multiple macrophage functions" at the Annual Meeting of the Research Society of Alcoholism in June 2007 and has been invited to speak on "Fcγ-receptor mediated phagocytosis is attenuated after acute *in vivo* or *in vitro* ethanol exposure due to attenuated Rho activation" at a Satellite Symposium on "Alcohol, Leukocytes, and Host Defense" at the Society of Leukocyte Biology meeting in November 2008 in Denver, CO. As a graduate student, he has shown to be a leader, having been elected class president during his second year in graduate school and is currently serving as the graduate representative of the Medical Council.

Department and Institute Highlights

Infectious Disease and Immunology Institute (InDII)

The Infectious Disease and Immunology Institute, co-directed by Drs. Katherine Knight (Microbiology and Immunology) and David Hecht (Infectious Diseases) was formed in response to the opportunity and need to facilitate formal interactions between basic scientists in bacteriology, virology and immunology with Infectious Disease clinician scientists from Infectious Diseases. The goal of these interactions is to promote joint research projects between basic and clinical scientists. InDII currently has over 25 active faculty members, divided into three research focus groups: Hospital Associated Infections and Antibiotic Resistance; Immunology and Infections Associated with Transplantation; and Emerging Infections.

The highlight of the spring '08 semester was our educational initiative, a seminar-course presented on Worldwide Emerging Infections. This year, the course, hosted by Dr. Thomas Gallagher, focused on the epidemiology, molecular pathogenesis and treatment for diseases caused by three viruses, human papillomavirus, influenza, and cytomegalovirus. The course format was a broad discussion of select recent journal articles, attended by graduate students, infectious disease fellows, medical students, and faculty from the Division of Infectious Diseases and the Department of Microbiology and Immunology. This course will be offered each spring, and in '09, the topic will be bacterial Infections of global significance. We invite all interested students, faculty and staff to participate in these lively and thoughtful paper discussions.

The major function of InDII since it's inception has been to bring scientists together, and this occurs on a regular basis, on Wednesdays at noon. This time is slotted for a journal club and a seminar series featuring both external and internal speakers. These seminars and journal clubs serve to promote fruitful discussions between clinical and basic scientists; some of these discussions have led to joint research projects.

A highlight of next year's InDII activities will be a symposium organized around the research expertise of our external advisory group, which is comprised of three internationally-recognized, outstanding scientists. The program will be announced this fall.

Research Activity at LUMC

Research Funding—New Awards, since January 2008

AWARDS 2008			
NAME	DEPARTMENT	Agency	DATE/AWARD
Karavitis, John	Burn and Shock Trauma Institute	NIH	1/1/08
Murdoch, Eva L.	Burn and Shock Trauma Institute	NIH	1/1/08
Majetschak, Matthias	Surgery/BSTI	DFG	6/1/08
Baker, Susan C.	Microbiology and Immunology Maguire Center	NIH	3/11/08
Gamelli, Robert	Surgery	USAMRAA	6/1/08
Robia, Seth L.	Physiology	NIH	7/1/08
Kovacs, Elizabeth J.	Burn and Shock Trauma Institute	NIH R21	7/1/08
Kovacs, Elizabeth J.	Burn and Shock Trauma Institute	NIH	7/10/08
Mathews, Herbert L. and Janusek, Linda	Microbiology and Immunology Maguire Center and School of Nursing	NIH	8/1/08
Knight, Katherine L.	Microbiology and Immunology Maguire Center	NIH T3	8/1/08
Foreman, Kimberly	Pathology Cancer Center	IDPH	1/1/08
Osipo, Clodia	Oncology Institute Cancer Center	ACS IL	1/1/08
Rizzo, Paola	Pathology Cancer Center	IDPH	1/1/08
Wiethoff, Christo- pher	Microbiology and Immunology Maguire Center	IDPH	1/1/08



Research News



**LOYOLA
MEDICINE**

Loyola University Chicago
Stritch School of Medicine

OFFICE OF RESEARCH SERVICES NEWSLETTER

SUMMER 2008

AWARDS 2008			
NAME	DEPARTMENT	Agency	DATE/AWARD
Cichon, Mark	EMS	IDPH	04/23/2008
Shoup, Margaret	Surgery	Riviera Country Club	05/01/2008
Mignery, Gregory	Physiology	NIH	04/01/2008
Qiao, Liang	Microbiology and Immunology Maguire Center	NIH	3/15/08
Baker, Susan C.	Microbiology and Immunology Maguire Center	NIH	4/3/08
Cui, Rutao	Oncology Institute	American Cancer Society	04/01/2008
Bidani, Anil	Medicine	IPA VA Hines	04/01/2008
Hemnway, Charles	Pediatrics	NIH	03/12/2008
Cao, Guichan	Preventive Medicine & Epidemiology	NIH	03/12/2008
Durzao-Arvizu, Ramon	Preventive Medicine & Epidemiology	IPA VA Hines	05/01/2008
Muthumalaippan (Muthu), Kuzhali	Surgery	NIH	06/01/2008
Hecht, David	Medicine	IPA VA Hines	06/01/2008
Greisler, Howard	Surgery	MOU Hines VA	06/01/2008
Greisler, Howard	Surgery	MOU Hines VA	06/01/2008
Majetschak	Oncology Institute	American Heart Association	06/01/2008
Cuevas, Bruce	Pharmacology	NIH	06/24/2008
Whelton, Paul	Preventive Medicine & Epidemiology	Arthur Foundation	12/11/2007
Whelton, Paul	Preventive Medicine & Epidemiology	MacNeal	12/11/2007
Cichon, Mark	EMS	Health Resources & Services Administration	03/01/2008
Roux, Gayle	Niehoff School of Nursing	Illinois Board of Higher Education	02/05/2008
Jacobson, Gloria	Niehoff School of Nursing	NIH	05/31/2008